Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life.

@article{Solish2005ProspectiveOS,
  title={Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life.},
  author={Nowell J. Solish and Antranik Benohanian and Jonathan W. Kowalski},
  journal={Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]},
  year={2005},
  volume={31 4},
  pages={405-13}
}
BACKGROUND Patients with primary axillary hyperhidrosis experience substantial functional impairment and reduced health-related quality of life (HRQOL). Few studies have comprehensively evaluated the effects of botulinum toxin type A (BoNT-A) on these symptoms. OBJECTIVE To prospectively assess the effects of BoNT-A on functional impairment associated with primary axillary hyperhidrosis. METHODS Patients treated with BoNT-A 50 U per axilla at baseline were assessed 4 and 12 weeks later… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

52-Week prospective randomized, double-blind placebo-controlled safety and efficacy study of 2 dosages of botulinum toxin type-A treatment for primary axillary hyperhidrosis

  • DA Glaser, NJ Lowe, N Eadie
  • Presented at American Academy of Neurology 56th…
  • 2004

Clinically meaningful improvements in health - related quality of life from etanercept therapy for patients with moderate to severe hyperhidrosis

  • S Feldman, AB Kimball, JM Woolley, R Zitnik
  • 2004

Enbrel® in Psoriasis Study Group. Clinically meaningful improvements in healthrelated quality of life from etanercept therapy for patients with moderate to severe hyperhidrosis

  • S Feldman, AB Kimball, JM Woolley, R Zitnik
  • Presented at the American Academy of Dermatology…
  • 2004

Quality-of-life effect of botulinum toxin type A on patients with primary axillary hyperhidrosis: results from a North American clinical study population

  • JW Kowalski, DA Glaser, NJ Lowe, A. Ravelo
  • Presented at the American Academy of Dermatology…
  • 2004

Validity and reliability of the Hyperhidrosis Disease Severity Scale (HDSS)

  • JW Kowalski
  • Presented at the American Academy of Dermatology…
  • 2004

Similar Papers

Loading similar papers…